Gong Jie, Zhu Shu-gan, Wu Cheng-yuan, Li Xin-gang, Liu Yu-guang, Ren Xiao-hui, Zhang Yuan
Department of Neurosurgery, Qilu Hospital of Shandong University, Ji'nan, China.
Zhonghua Yi Xue Za Zhi. 2012 Nov 6;92(41):2889-92.
To explore the functions of NF2, TIMP-3 and THBS1 genes in the tumorigenesis or progression of meningiomas and analyze the values of these genes in early diagnosis, therapy and prognostic evaluation in meningiomas.
A total of 66 cases with histological sections of meningiomas, including solitary (SMs, n = 30) and multiple meningiomas (MMs, n = 36), were retrieved from our departmental archives. All cases were regrouped as benign, atypical and anaplastic (malignant) by hematoxylin & eosin staining according to the recently published WHO classification of nervous system tumors. Genomic DNA was extracted from tumor sections and methylation-specific polymerase chain reaction (MSP) performed to detect the CpG methylation status. Normal brain tissue was used as the control group. And then the differences of methylation rate between SMs and MMs tissues and among different subgroups were analyzed by statistical analyses.
The results of methylation in different types of meningiomas demonstrated that the rates of NF2, TIMP-3 and THBS1 methylation were 26.7% (8/30), 16.7% (5/30) and 36.7% (11/30) in 30 SMs tissues and 30.6% (11/36), 22.2% (8/36) and 22.2% (8/36) in 36 MMs tissues respectively. But no aberrant methylation of NF2, TIMP-3 and THBS1 genes was found in normal brain tissue. No significant differences in three types of gene methylation rates existed between SMs and MMs in the I-III grade meningiomas. Nevertheless, there was great difference between grades I, II and III in SMs and MMs while no significant difference was found between grades II and III.
The methylation of NF2, TIMP-3 and THBS1 is correlated with the tumorigenesis of meningiomas (grade II and III). As an important pathogenetic cause of meningiomas, it may be used as a clinical tool for an early diagnosis of meningiomas.
探讨NF2、TIMP - 3和THBS1基因在脑膜瘤发生或进展中的作用，并分析这些基因在脑膜瘤早期诊断、治疗及预后评估中的价值。
从我院科室档案中检索出66例有脑膜瘤组织切片的病例，包括孤立性脑膜瘤（SMs，n = 30）和多发性脑膜瘤（MMs，n = 36）。根据最近发布的世界卫生组织神经系统肿瘤分类，通过苏木精和伊红染色将所有病例重新分为良性、非典型和间变性（恶性）。从肿瘤切片中提取基因组DNA，并进行甲基化特异性聚合酶链反应（MSP）以检测CpG甲基化状态。正常脑组织用作对照组。然后通过统计学分析来分析SMs和MMs组织之间以及不同亚组之间甲基化率的差异。
不同类型脑膜瘤的甲基化结果表明，30例SMs组织中NF2、TIMP - 3和THBS1的甲基化率分别为26.7%（8/30）、16.7%（5/30）和36.7%（11/30），36例MMs组织中分别为30.6%（11/36）、22.2%（8/36）和22.2%（8/36）。但在正常脑组织中未发现NF2、TIMP - 3和THBS1基因的异常甲基化。在I - III级脑膜瘤中，SMs和MMs的三种基因甲基化率无显著差异。然而，SMs和MMs的I、II和III级之间存在很大差异，而II级和III级之间未发现显著差异。
NF2、TIMP - 3和THBS1的甲基化与脑膜瘤（II级和III级）的发生相关。作为脑膜瘤的重要发病原因，它可能用作脑膜瘤早期诊断的临床工具。
